Subscribe
|
Contact Us
|
Ablexis Accepts $12 Million Venture Capital Funding
Thursday, June 03, 2010
5:29:00 AM PDT | VentureDeal Staff
San Francisco, California -- Biotechnology company
Ablexis
has secured $12 million in its first round of venture capital financing.
Ablexis is developing a proprietary transgenic mouse platform to assist in the discovery of human therapeutic antibodies.
Third Rock Ventures led the round, which also included Pfizer Strategic Investments. The company said it would use the proceeds to continue advancing the development of its platform.
Email Page
|
Print Page
Loading
Want unlimited access to the
complete database
with thousands of technology companies, VCs and transactions for only $25 per month?
Start your
Free 14 Day Trial
now – no obligation or credit card required.
